List of Excipients in Branded Drug ZENPEP

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	ZENPEP	pancrelipase	54868-6435	CARRAGEENAN
Physicians Total Care Inc	ZENPEP	pancrelipase	54868-6435	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	ZENPEP	pancrelipase	54868-6435	CROSCARMELLOSE SODIUM
Physicians Total Care Inc	ZENPEP	pancrelipase	54868-6435	FERRIC OXIDE YELLOW
Physicians Total Care Inc	ZENPEP	pancrelipase	54868-6435	HYDROGENATED CASTOR OIL
Physicians Total Care Inc	ZENPEP	pancrelipase	54868-6435	HYPROMELLOSE PHTHALATE
Physicians Total Care Inc	ZENPEP	pancrelipase	54868-6435	HYPROMELLOSES

ZENPEP Excipient Strategy and Commercial Opportunities

Last updated: October 12, 2026

ZENPEP is a delayed-release pancrelipase capsule used as pancreatic enzyme replacement therapy for exocrine pancreatic insufficiency caused by cystic fibrosis, chronic pancreatitis, pancreatectomy, and other conditions. Its commercial value depends on more than enzyme potency. The product requires controlled pellet manufacture, enteric protection, acid resistance, dose flexibility, stability through storage, and reliable administration with food.

The strongest excipient opportunities are in enteric coating systems, moisture control, pellet processing, capsule alternatives, pediatric delivery, and manufacturing technologies that reduce dose variability. Direct substitution is difficult because pancrelipase is a mixture of lipase, protease, and amylase enzymes with product-specific performance requirements.

What is ZENPEP and how does its formulation work?

ZENPEP contains porcine-derived pancrelipase in delayed-release capsules. Each capsule contains enteric-coated, bicarbonate-buffered pancrelipase pellets. The pellets are designed to resist gastric acid and release enzymes in the duodenum and proximal small intestine.

Attribute	ZENPEP profile
Active ingredient	Pancrelipase, a mixture of lipase, protease, and amylase
Source	Porcine pancreatic tissue
Dosage form	Delayed-release capsule
Strengths	3,000, 5,000, 10,000, 15,000, 20,000, 25,000, 40,000, and 50,000 lipase units
Main use	Exocrine pancreatic insufficiency
Administration	Taken during or immediately after meals and snacks
Release target	Small intestine
Regulatory status	FDA-approved prescription drug
Product owner	Nestlé Health Science
NDA	022210

The product’s clinical dosing is expressed primarily in lipase units. Patients often require multiple capsules per meal, creating an opportunity for higher-strength units, fewer capsules, and more flexible pediatric dosing. The FDA-approved prescribing information is the controlling source for dose, administration, warnings, and product composition (U.S. Food and Drug Administration [FDA], 2023).

What excipients are used in ZENPEP?

ZENPEP uses excipients for pellet formation, lubrication, flow, moisture control, enteric protection, and capsule manufacture. The product label identifies excipients including colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, talc, and triethyl citrate. Capsule shells contain gelatin and colorants, including titanium dioxide and approved FD&C colors, depending on capsule strength (FDA, 2023).

Excipient or excipient class	Likely formulation function
Microcrystalline cellulose	Pellet core, binder, structural support
Hypromellose	Film-forming polymer and coating component
Triethyl citrate	Plasticizer that improves coating flexibility
Talc	Anti-tacking and coating-process aid
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Crospovidone	Processing aid and structural component
Gelatin	Hard capsule shell
Titanium dioxide and FD&C colors	Opacity and product identification

The commercially important excipient system is the enteric coating. A coating that is too permeable can release enzymes prematurely in the stomach. A coating that is too resistant can delay release beyond the intended intestinal region. The formulation must also protect enzymes from humidity, heat, mechanical stress, and interaction with other capsule or pellet components.

What formulation characteristics create value in ZENPEP?

Four performance attributes determine whether an excipient strategy has practical value.

Acid resistance

Pancreatic enzymes are vulnerable to gastric acid. The coating must maintain integrity at low pH and release under intestinal conditions. Enteric polymers, plasticizer concentration, coating thickness, curing conditions, and pellet surface characteristics all affect this balance.

Enzyme stabilization

Pancrelipase is a protein-based active ingredient. Moisture, temperature, pH, and shear can reduce activity. Excipients that improve water management and reduce enzyme migration can improve shelf life and batch consistency.

Dose uniformity

A capsule may contain thousands of pellets. Each pellet must have reliable enzyme loading and coating coverage. Segregation during blending, filling, transport, or capsule opening can cause dose variability.

Administration flexibility

Patients may open capsules and sprinkle pellets on soft acidic food, subject to label instructions. Pellets must remain intact during handling and must not be crushed or chewed. Better pellet strength, taste masking, and controlled particle size can improve pediatric use and adherence.

Which excipient technologies could improve ZENPEP?

Enteric polymer optimization

The most direct opportunity is a next-generation enteric coating with tighter release control. Suitable development areas include:

• Lower coating weight without loss of acid resistance.
• Improved coating uniformity on small pellets.
• Reduced variability after long-term storage.
• Lower-temperature coating processes.
• Reduced dependence on organic solvents.
• Improved compatibility with enzyme-loaded cores.

Methacrylic acid copolymers, hypromellose phthalate, hypromellose acetate succinate, and related enteric polymers are established technical options. The commercial advantage would come from performance and manufacturing consistency rather than simple substitution of one polymer for another.

Moisture-barrier systems

Moisture control is critical for enzyme products. Opportunities include:

• High-barrier blister packaging.
• Desiccant-containing bottles.
• Moisture-resistant capsule shells.
• Coatings that limit water ingress.
• Low-water-activity excipient systems.
• Improved container-closure integrity.

Packaging improvements may be easier to commercialize than a new active formulation because they can address stability without changing the clinical dose. Regulatory impact depends on whether the change affects dissolution, release, potency, or shelf life.

Pediatric and sprinkle formulations

Children with cystic fibrosis often need flexible dosing and may have difficulty swallowing capsules. Commercial opportunities include:

• Smaller capsules with the same pellet technology.
• Unit-dose sachets.
• Ready-to-administer sprinkle products.
• Improved taste masking.
• Pellets designed for mixing with approved acidic foods.
• More granular strength combinations for weight-based dosing.

A pediatric product must preserve enteric protection after capsule opening. Taste-masking excipients cannot compromise pellet dissolution or release. Sweeteners and flavors can also introduce stability and compatibility issues.

Capsule-shell alternatives

Gelatin is familiar, inexpensive, and widely accepted, but vegetarian or non-animal capsule shells may expand market access. Hypromellose and pullulan shells are potential alternatives. The key technical issue is moisture transfer. A shell with different water content or permeability can alter pellet stability and capsule performance.

A shell change may require comparative stability, dissolution, moisture-uptake, and bioequivalence work. The commercial opportunity is strongest in markets where vegetarian, halal, kosher, or non-porcine requirements influence prescribing or patient acceptance.

High-load pellet cores

Higher enzyme loading could reduce capsule count. The challenge is maintaining uniform distribution of lipase, protease, and amylase while preserving pellet strength and coating coverage. Higher loading may reduce excipient mass but increase processing sensitivity.

A high-load platform could support 60,000- or 75,000-unit capsules, although any new strength would require regulatory review and clinical or bioequivalence support. The commercial benefit would be greatest for adults requiring high meal doses.

How does ZENPEP compare with competing pancreatic enzyme products?

ZENPEP competes with Creon, Pertzye, Pancreaze, and Viokace. Creon and other delayed-release products use different formulation and manufacturing approaches, even though all provide pancrelipase.

Product	Release design	Key commercial position
ZENPEP	Delayed-release enteric-coated pellets in capsules	Broad strength range and sprinkle administration
Creon	Delayed-release minimicrospheres in capsules	Large installed base and strong physician familiarity
Pertzye	Delayed-release capsules with bicarbonate-buffered particles	Differentiated buffering approach
Pancreaze	Delayed-release capsules containing enteric-coated beads	Established PERT competitor
Viokace	Immediate-release tablets used with a proton-pump inhibitor	Different administration and acid-control requirements

Creon is the closest commercial comparator. Product switching is constrained by physician familiarity, patient titration, insurance coverage, and differences in capsule and pellet performance. A generic applicant cannot assume that a formulation with the same nominal lipase strength will be substitutable without demonstrating comparable product performance.

What FDA regulatory issues affect ZENPEP excipient changes?

ZENPEP is regulated as a drug, not as a biologic. Biosimilar approval is therefore not the relevant pathway. Generic applicants would generally pursue an abbreviated new drug application, while significant formulation changes by the brand sponsor may require a supplemental NDA or a new NDA depending on the change.

The key regulatory tests include:

• Assay of lipase, protease, and amylase activity.
• Enzyme-specific potency and stability.
• Acid resistance.
• Intestinal release and dissolution.
• Pellet size and coating uniformity.
• Content uniformity.
• Comparative bioavailability or bioequivalence where required.
• Demonstration that inactive ingredients do not alter performance.
• Container-closure and extractables or leachables assessment.

FDA has issued product-specific guidance for pancrelipase products. The guidance reflects the difficulty of demonstrating sameness for products containing multiple enzymes and multiparticulate delivery systems (FDA, 2018).

What is the Orange Book and patent status of ZENPEP?

ZENPEP is listed in FDA’s Orange Book under NDA 022210. The Orange Book identifies approved products, therapeutic equivalence evaluations, patent information submitted by sponsors, and regulatory exclusivity where applicable (FDA, 2024).

Patent risk for ZENPEP is likely to center on:

• Enteric-coated pancrelipase pellets.
• Multiparticulate dosage forms.
• Enzyme stabilization.
• Bicarbonate-buffered formulations.
• Release-control coatings.
• Manufacturing methods.
• Capsule and pellet combinations.
• Specific dosing or administration methods.

A generic applicant must assess both listed patents and unlisted freedom-to-operate risks. Formulation patents can remain commercially relevant even when an earlier composition patent has expired. Method-of-use patents may affect labeling strategy, although they generally create different infringement and carve-out questions than formulation claims.

When could generic ZENPEP competition emerge?

Generic entry depends on FDA approval, Orange Book patent certifications, litigation, settlements, and the ability to demonstrate therapeutic equivalence. A Paragraph IV certification may trigger patent litigation if an applicant alleges that listed claims are invalid, unenforceable, or not infringed.

The principal generic-entry scenarios are:

Scenario	Commercial effect
First approved generic with no blocking litigation	Rapid price erosion and payer substitution
Paragraph IV challenge followed by settlement	Delayed entry with a negotiated launch date
Non-infringing formulation design	Potential entry after regulatory approval without direct copying
Authorized generic or brand-linked competitor	Lower-price competition controlled by the sponsor
Multiple ANDA approvals	Greater discounting and reimbursement pressure

Pancrelipase products have a higher technical barrier than conventional immediate-release tablets. Generic competition may be slower because applicants must replicate enzyme activity, pellet performance, acid resistance, and intestinal release. The barrier is formulation and analytical comparability, not the complexity of the active molecule alone.

Which licensing and partnership opportunities exist?

The most attractive licensing targets are technologies that solve a defined commercial problem:

1. Enteric coatings with improved acid resistance and lower process variability.
2. Moisture-barrier packaging validated for enzyme products.
3. Vegetarian capsule shells with low moisture transfer.
4. Pediatric sprinkle systems with taste masking.
5. High-load multiparticulate manufacturing.
6. Continuous coating and in-line pellet inspection.
7. Analytical methods for enzyme-specific dissolution and potency.
8. Stable unit-dose packaging for adherence and institutional use.

A formulation technology provider could license a polymer system, coating process, capsule platform, or analytical method to a pancreatic enzyme manufacturer. The strongest deal structures would tie royalties to approved strengths, commercial sales, or manufacturing savings rather than rely solely on upfront payments.

What revenue exposure and commercial opportunities does ZENPEP have?

Pancreatic enzyme replacement is a chronic-use market. Patients commonly require treatment with every meal and snack, creating recurring prescription volume. Revenue is exposed to:

• Generic entry.
• Payer formulary exclusions.
• Product shortages.
• Copay burden.
• Capsule-count fatigue.
• Patient switching between PERT brands.
• Cystic fibrosis treatment advances.
• Improvements in pancreatic disease diagnosis.
• Expansion into post-pancreatectomy and chronic pancreatitis populations.

Excipient-led product improvements can support premium pricing only when they produce measurable benefits, such as fewer capsules, easier pediatric administration, longer shelf life, better storage conditions, or improved adherence. A reformulation that merely changes a nonfunctional excipient is unlikely to create durable commercial differentiation.

How strong is the ZENPEP formulation strategy?

ZENPEP has a technically defensible formulation profile because its value depends on a controlled multiparticulate system rather than a simple capsule fill. The strongest barriers are:

• Enzyme-specific analytical testing.
• Enteric-coating performance.
• Stability under moisture stress.
• Pellet uniformity.
• Dose flexibility across multiple strengths.
• Administration requirements after capsule opening.
• Manufacturing experience with pancrelipase.

The estate is less defensible if competitors can reproduce equivalent pellet performance using conventional enteric polymers and standard capsule technology. Patent strength therefore depends on claim scope, enforceability, remaining term, manufacturing know-how, and the ability to distinguish the product through pediatric, high-strength, or packaging improvements.

Key Takeaways

• ZENPEP is a delayed-release pancrelipase capsule with enteric-coated pellets.
• The central excipient function is acid protection and controlled intestinal release.
• Microcrystalline cellulose, hypromellose, triethyl citrate, talc, magnesium stearate, colloidal silicon dioxide, and capsule-shell materials support the formulation and manufacturing process.
• The strongest commercial opportunities are moisture protection, pediatric sprinkle delivery, capsule-shell alternatives, high-load pellets, and tighter enteric-release control.
• Creon is the closest major competitor; Pertzye, Pancreaze, and Viokace use different formulation and administration approaches.
• Generic competition is technically more difficult than conventional tablet substitution because pancrelipase contains multiple enzyme activities and requires multiparticulate performance.
• Excipient innovation has commercial value when it reduces capsule burden, improves pediatric use, extends stability, or lowers manufacturing variability.
• ZENPEP is an FDA-approved drug listed under NDA 022210. Patent and Paragraph IV analysis should focus on formulation, manufacturing, release-control, and method-of-use claims.

FAQs

Can ZENPEP capsules be opened and mixed with food?

Yes. The prescribing information permits capsule contents to be sprinkled on certain soft acidic foods, provided the pellets are not crushed or chewed. The mixture should be administered promptly and followed by liquid according to labeling instructions (FDA, 2023).

Why are enteric coatings important in pancrelipase products?

Enteric coatings protect pancreatic enzymes from gastric acid and enable release in the small intestine. Coating failure can reduce enzyme activity before the product reaches the intended site of action.

Could a vegetarian capsule replace the gelatin capsule in ZENPEP?

Potentially, but the replacement would require evaluation of moisture transfer, stability, dissolution, capsule performance, and regulatory comparability. Hypromellose shells are the most established alternative platform.

Does ZENPEP have biosimilar competition?

No. ZENPEP is a drug product, not a biologic subject to the biosimilar pathway. Competition would generally arise through generic or other drug-approval pathways.

Which excipient change would have the highest commercial value?

A change that enables a stable, high-strength, low-capsule-count product or a reliable pediatric sprinkle presentation would likely have greater commercial value than a cosmetic capsule-shell or color change.

References

1. U.S. Food and Drug Administration. (2018). Product-specific guidance for pancrelipase delayed-release capsules. FDA.

2. U.S. Food and Drug Administration. (2023). ZENPEP (pancrelipase) delayed-release capsules: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

5. Nestlé Health Science. (2024). ZENPEP product information. Nestlé Health Science.